news
press releases
 
2018, November 6: American Heart Association publishes AGE Reader meta-analysis
79.27 Kb
2018, February 28: Diagnoptics' AGE Reader mu receives market approval in South Korea
172.83 Kb
2017, September 12: UbiQ secures 2.7 mioEUR EUROSTARS grant to tackle SUMOylation
305 Kb
2017, June 29: Diagnoptics appoints MSP bodmann GmbH as new distributor in Germany
280.69 Kb
2017, February 20: Mercachem and UbiQ join forces to tackle SUMOylation
97.17 Kb
2017, February 3: ViciniVax announces first patient treated in Phase I study with immunotherapy Vvax001 for HPV-related precancers and cancer
424.25 Kb
2016, February 12: Diagnoptics receives Chinese market approval for AGE Reader SU
358.16 Kb
2016, January 7: New patent granted to Diagnoptics in Japan and EU
345.28 Kb
2015, September 11: Diagnoptics receives Japanese market approval for AGE Reader mu
336.24 Kb
2015, September 7: Diagnoptics nominated for Deloitte Technology Fast50
341.16 Kb
2015, April 29: Ubiquigent announces an exclusive collaboration with UbiQ
50.58 Kb
2015, January 26: BBB Therapeutics filed for bankruptcy
557.03 Kb
2014, September 30: BBB Therapeutics New Management & Name
93.13 Kb
2014, September 12: to-BBB Announces Positive Data from Phase 1 Clinical Study
82.06 Kb
2014, September 9: Anders Harfstrand Joins to-BBB as Chief Executive Officer
68.55 Kb
2014, June 30: to-BBB Announces Successful €10 Million Financing
100.47 Kb
2014, May 9: Avacta in collaboration with UbiQ Bio
0 Kb
2014, January 9: to-BBB Appoints Leonard Kruimer as Chief Financial Officer
78.83 Kb
2013, December 17: to-BBB Initiated Phase I Study in Healthy Volunteers with 2B3-201
77.19 Kb
2013, December 11: to-BBB and Sihuan Enter into Collaboration Agreement
92.05 Kb
2013, December 5: to-BBB Hires Dr. Carlos de Sousa as Chief Business Office
73.38 Kb
2013, October 16: High-Tech Gründer Fonds and Bayern Kapital lead investment in Photonics Healthcare
0 Kb
2013, October 2: to-BBB Presents Data on 2B3-201 for Multiple Sclerosis
71.15 Kb
2013, September 26: to-BBB Presents Clinical Data on Lead Product 2B3-101
77.8 Kb
2013, August 19: to-BBB Receives IND Approval for Novel Brain Cancer Drug, 2B3-101
79.89 Kb
2013, June 24: UbiQ and Neuroscience Campus Amsterdam join forces to develop treatments for Parkinson’s disease and other neurodegenerative illnesses
91.77 Kb
2013, April 25: to-BBB closes EUR 2.5 million financing round to broaden clinical brain tumor study
69.14 Kb
2013, March 13: Intravacc and ViciniVax sign license agreement to advance the development of a novel vaccine against cervical cancer
111.77 Kb
2013, March 11: Launch of UbiQ-Probes, activity-based DUB probes
0 Kb
2013, February 6: Launch of UbiQ-PEP, custom ubiquitinated peptide synthesis
0 Kb
2013, January 8: ALS Therapy Development Institute and to-­‐BBB Collaborate on Potential Treatments for Motor Neuron Disease
492.76 Kb
2012, November 28: to-BBB receives Frost & Sullivan Technology Innovation Award
971.13 Kb
2012, July 16: to-BBB presents and publishes data on 2B3-201 for neuroinflammation and receives Innovation Credit for product development
78.27 Kb
2012, April 17: to-BBB receives Michael J. Fox Foundation funding for Parkinson’s disease research
75.48 Kb
2012, February 6: DiagnOptics and PATH partner on clinical research project on diabetes screening in India
431.18 Kb
2012, January 25: FlexGen, LUMC and BGI collaboration
80.05 Kb
2012, January 6: FlexGen expands to new location
0 Kb
2011, December 19: to-BBB receives International Innovation grant to support partnership with top-5 pharma company
76.48 Kb
2011, December 19: DiagnOptics receives CE mark approval for Diab-spot
0 Kb
2011, november 24: to-BBB interview in Telegraaf
463.59 Kb
2011, October 5: to-BBB shortlisted for EuropaBio's Most Innovative European Biotech SME Award
378.4 Kb
2011, September 29: NeuroVive and to-BBB awarded Eurostars grant for development of stroke therapy
101.33 Kb
2011, August 29: to-BBB builds for success with Chief Medical Officer and new group of investors
672.04 Kb
2011, June 27: to-BBB starts clinical trial in patients with brain metastases
667.28 Kb
2011, April 9: New product for early diabetes detection, Diab-spot, introduced
88.86 Kb
2011, March 31: to-BBB obtains government loan of €1.2 million for clinical trial in brain cancer
671.21 Kb
2011, March 30: DiagnOptics receives Health Canada approval for the AGE Reader
88.41 Kb
2011, February 3: to‐BBB realizes €4M investment round
147.82 Kb
2011, January 5: Synageva BioPharma Corp and to-BBB to collaborate on brain drug delivery for rare diseases
174.35 Kb
2010, December 10: Boston Biochem and UbiQ to collaborate on di-Ubiquitin chains
101.9 Kb
2010, October 25: NeuroVive and to-BBB to jointly develop therapy for stroke
152.2 Kb
2010, August 23: FDA grants Orphan Drug Status for to-BBB’s lead product
96.86 Kb
2010, June 14: to-BBB receives positive opinion for Orphan Drug Designation
93.43 Kb
2010, May 20: to-BBB announces brain drug delivery pilot study with Janssen Pharmaceutica NV for CNS diseases
91.38 Kb
2010, mei 17: Mibiton financiert DNA synthese apparatuur van FlexGen
517.69 Kb
2010, March 3: to-BBB and GSK to collaborate on brain delivery of a biologic product
90.88 Kb
2010, February 24: NGI 250kEUR grant for Photonics Healthcare
0 Kb
2010, January 7: to-BBB announces two additional pharma collaborations on brain drug delivery
90.68 Kb
2010, January 4: AGE Reader in HealthDirect Diabetes
888.19 Kb
2009, December 22: to-BBB and Lundbeck to join forces on brain delivery of antibodies for CNS diseases
85.4 Kb
2009, November 16: The newest version of the AGE Reader receives CE mark approval
309.55 Kb
2009, November 3: to-BBB announces collaboration with Genzyme on brain delivery of biologics for neurodegenerative diseases
99.27 Kb
2009, September 17: to-BBB technology will be used by MedImmune to evaluate brain drug delivery mechanism
96.73 Kb
2009, August 20: Acceleration of the development of to-BBB’s brain cancer treatment
247.9 Kb
2009, August 6: to-BBB climbs up the international CNS drug delivery ranking
667.2 Kb
2009, July 9: Professor Bart de Strooper and to-BBB to collaborate on brain delivery of anti-Alzheimer’s antibodies
115.3 Kb
2009, juni 23: Het Financieele Dagblad: to-BBB
4678.51 Kb
2009, June 22: The Netherlands Cancer Institute (NKI) and to-BBB to collaborate on brain delivery of anti-cancer drugs
685.42 Kb
2009, June 11: FlexGen among FEM Tech 25 winners
57.88 Kb
2009, May 12: U.S. Army funds TNO, and to-BBB to investigate protecting soldier’s brains from nerve agents
125.35 Kb
2009, March 2: FlexGen closes new round of financing
74.5 Kb
2009, February 3: to-BBB moves into commercialization mode with new CEO Willem van Weperen
99.77 Kb
2008, November 12: to-BBB and Taiwanese ITRI sign exclusive license agreement
125.2 Kb
2008, maart 19: Het Financieele Dagblad: Nieuw instrument meet risico op hartinfarct met een flits (DiagnOptics)
70.28 Kb
2007, december 14: VenGen ondersteunt het Dwarslaesie Fonds
320.7 Kb
2007, July 6: AESCAP VENTURE INVESTS EUR 4 MIO IN TO-BBB
150.19 Kb
2007, juni 16: FEM Business; TECH25: de 25 briljantste bedrijven van Nederland (to-BBB)
1653.09 Kb
2006, October 26: Press release of American Diabetes Association (DiagnOptics)
44.21 Kb
2006, Oktober 26: FlexGen in Biotech News
199.24 Kb
2006, augustus 24: Elsevier Voedingsmiddelen Industrie Magazine; Lactive Natuurlijk Bioactief
2117.63 Kb
2006, juni 10: FEM Business; De 25 briljantste start-ups van Nederland (Lactive)
272.99 Kb
2006, May 8: DiagnOptics' AGE Reader receives CE mark
32.57 Kb
2006, March 7: VenGen relaunches the company website
66.7 Kb
2005, December 8: CNS drug targeting technology 2B-Trans™ to be part of Dutch Technology Foundation grant at Leiden University
178.91 Kb
2005, October 20: to-BBB secures grant from Sanfilippo Foundation
175.56 Kb
2005, juni 20: FEM Business: TECH25; de briljantste bedrijven van Nederland (to-BBB)
390.66 Kb
2005, mei 31: Het Financieele Dagblad; Medisch paard van Troje (to-BBB)
1435.95 Kb
2005, May 24: to-BBB signs agreement with Genmab on 2B-Trans™ technology
34.73 Kb
2005, March 21 (Dutch): to-BBB eerste in tender Innovatiesubsidie Samenwerkingsprojecten
32.25 Kb
2005, March 14: to-BBB announces research collaboration with Biogen Idec
32.51 Kb
2004, juni 5: FEM Business; TECH25: de briljantste bedrijven van Nederland (to-BBB)
444.91 Kb
 
 
copyright 2018 - VenGen - disclaimer